Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Neuropsychopharmacology

Retrieve available abstracts of 33 articles:
HTML format

Single Articles

    March 2023
  1. O'DONNELL P, Dong C, Murthy V, Asgharnejad M, et al
    The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
    Neuropsychopharmacology. 2023 Mar 16. doi: 10.1038/s41386-023-01560.
    PubMed     Abstract available

    February 2023
  2. CHEN X, Song X, Ongur D, Du F, et al
    Association of default-mode network neurotransmitters and inter-network functional connectivity in first episode psychosis.
    Neuropsychopharmacology. 2023 Feb 14. doi: 10.1038/s41386-023-01546.
    PubMed     Abstract available

    December 2022
  3. YANG C, Zhang W, Liu J, Yao L, et al
    Disrupted subcortical functional connectome gradient in drug-naive first-episode schizophrenia and the normalization effects after antipsychotic treatment.
    Neuropsychopharmacology. 2022 Dec 10. doi: 10.1038/s41386-022-01512.
    PubMed     Abstract available

  4. EGERTON A, Griffiths K, Casetta C, Deakin B, et al
    Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration.
    Neuropsychopharmacology. 2022 Dec 1. doi: 10.1038/s41386-022-01508.
    PubMed     Abstract available

    November 2022
  5. MOYA NA, Yun S, Fleps SW, Martin MM, et al
    The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
    Neuropsychopharmacology. 2022 Nov 15. pii: 10.1038/s41386-022-01492.
    PubMed     Abstract available

  6. FENG N, Palaniyappan L, Robbins TW, Cao L, et al
    Working memory processing deficit associated with a nonlinear response pattern of the anterior cingulate cortex in first-episode and drug-naive schizophrenia.
    Neuropsychopharmacology. 2022 Nov 14. pii: 10.1038/s41386-022-01499.
    PubMed     Abstract available

    October 2022
  7. LENCZ T, Moyett A, Argyelan M, Barber AD, et al
    Frontal lobe fALFF measured from resting-state fMRI as a prognostic biomarker in first-episode psychosis.
    Neuropsychopharmacology. 2022 Oct 5. pii: 10.1038/s41386-022-01470.
    PubMed     Abstract available

    September 2022
  8. VINOGRADOV S, Chafee MV, Lee E, Morishita H, et al
    Psychosis spectrum illnesses as disorders of prefrontal critical period plasticity.
    Neuropsychopharmacology. 2022 Sep 30. pii: 10.1038/s41386-022-01451.
    PubMed     Abstract available

  9. HOWES OD, Cummings C, Chapman GE, Shatalina E, et al
    Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes.
    Neuropsychopharmacology. 2022 Sep 2. pii: 10.1038/s41386-022-01426.
    PubMed     Abstract available

    August 2022
  10. SCHWARZER JM, Meyhoefer I, Antonucci LA, Kambeitz-Ilankovic L, et al
    The impact of visual dysfunctions in recent-onset psychosis and clinical high-risk state for psychosis.
    Neuropsychopharmacology. 2022 Aug 18. pii: 10.1038/s41386-022-01385.
    PubMed     Abstract available

    March 2022
  11. ALNAFISAH RS, Reigle J, Eladawi MA, O'Donovan SM, et al
    Assessing the effects of antipsychotic medications on schizophrenia functional analysis: a postmortem proteome study.
    Neuropsychopharmacology. 2022 Mar 30. pii: 10.1038/s41386-022-01310.
    PubMed     Abstract available

  12. ZHAO Q, Cao H, Zhang W, Li S, et al
    A subtype of institutionalized patients with schizophrenia characterized by pronounced subcortical and cognitive deficits.
    Neuropsychopharmacology. 2022 Mar 8. pii: 10.1038/s41386-022-01300.
    PubMed     Abstract available

  13. TSITSIPA E, Rogers J, Casalotti S, Belessiotis-Richards C, et al
    Selective 5HT3 antagonists and sensory processing: a systematic review.
    Neuropsychopharmacology. 2022;47:880-890.
    PubMed     Abstract available

  14. DAO M, Stoveken HM, Cao Y, Martemyanov KA, et al
    The role of orphan receptor GPR139 in neuropsychiatric behavior.
    Neuropsychopharmacology. 2022;47:902-913.
    PubMed     Abstract available

    February 2022
  15. SEHATPOUR P, Javitt DC, De Baun HM, Carlson M, et al
    Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
    Neuropsychopharmacology. 2022;47:711-718.
    PubMed     Abstract available

    January 2022
  16. KIMOTO S, Hashimoto T, Berry KJ, Tsubomoto M, et al
    Expression of actin- and oxidative phosphorylation-related transcripts across the cortical visuospatial working memory network in unaffected comparison and schizophrenia subjects.
    Neuropsychopharmacology. 2022 Jan 15. pii: 10.1038/s41386-022-01274.
    PubMed     Abstract available

  17. CARREIRA FIGUEIREDO I, Borgan F, Pasternak O, Turkheimer FE, et al
    White-matter free-water diffusion MRI in schizophrenia: a systematic review and meta-analysis.
    Neuropsychopharmacology. 2022 Jan 15. pii: 10.1038/s41386-022-01272.
    PubMed     Abstract available

    November 2021
  18. KIEMES A, Gomes FV, Cash D, Uliana DL, et al
    GABAA and NMDA receptor density alterations and their behavioral correlates in the gestational methylazoxymethanol acetate model for schizophrenia.
    Neuropsychopharmacology. 2021 Nov 6. pii: 10.1038/s41386-021-01213.
    PubMed     Abstract available

    October 2021
  19. KIM M, Lee TH, Park H, Moon SY, et al
    Thalamocortical dysrhythmia in patients with schizophrenia spectrum disorder and individuals at clinical high risk for psychosis.
    Neuropsychopharmacology. 2021 Oct 4. pii: 10.1038/s41386-021-01180.
    PubMed     Abstract available

  20. PELIN H, Ising M, Stein F, Meinert S, et al
    Identification of transdiagnostic psychiatric disorder subtypes using unsupervised learning.
    Neuropsychopharmacology. 2021;46:1895-1905.
    PubMed     Abstract available

    September 2021
  21. TUOMINEN L, Romaniuk L, Milad MR, Goff DC, et al
    Impairment in acquisition of conditioned fear in schizophrenia.
    Neuropsychopharmacology. 2021 Sep 29. pii: 10.1038/s41386-021-01193.
    PubMed     Abstract available

  22. MILLARD SJ, Bearden CE, Karlsgodt KH, Sharpe MJ, et al
    The prediction-error hypothesis of schizophrenia: new data point to circuit-specific changes in dopamine activity.
    Neuropsychopharmacology. 2021 Sep 29. pii: 10.1038/s41386-021-01188.
    PubMed     Abstract available

  23. EUM S, Hill SK, Alliey-Rodriguez N, Stevenson JM, et al
    Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.
    Neuropsychopharmacology. 2021;46:1802-1810.
    PubMed     Abstract available

  24. LAM M, Chen CY, Ge T, Xia Y, et al
    Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics.
    Neuropsychopharmacology. 2021;46:1788-1801.
    PubMed     Abstract available

    August 2021
  25. ABDALLAH CG, Mason GF
    Novel approaches to estimate prefrontal synaptic strength in vivo in humans: of relevance to depression, schizophrenia, and ketamine.
    Neuropsychopharmacology. 2021 Aug 2. pii: 10.1038/s41386-021-01122.

  26. BRALTEN J, Mota NR, Klemann CJHM, De Witte W, et al
    Genetic underpinnings of sociability in the general population.
    Neuropsychopharmacology. 2021;46:1627-1634.
    PubMed     Abstract available

    July 2021
  27. SMUCNY J, Dienel SJ, Lewis DA, Carter CS, et al
    Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia.
    Neuropsychopharmacology. 2021 Jul 20. pii: 10.1038/s41386-021-01089.
    PubMed     Abstract available

  28. FERRARELLI F, Phillips ML
    PFC neuromodulation with theta burst stimulation to impact behavior and neural network activity in schizophrenia and bipolar disorder.
    Neuropsychopharmacology. 2021 Jul 7. pii: 10.1038/s41386-021-01086.

  29. GOLDWASER EL, Chiappelli J, Kvarta MD, Du X, et al
    White matter in prolonged glucocorticoid response to psychological stress in schizophrenia.
    Neuropsychopharmacology. 2021 Jul 1. pii: 10.1038/s41386-021-01077.
    PubMed     Abstract available

    June 2021
  30. AVRAM M, Grothe MJ, Meinhold L, Leucht C, et al
    Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia.
    Neuropsychopharmacology. 2021 Jun 29. pii: 10.1038/s41386-021-01070.
    PubMed     Abstract available

  31. TRONCHIN G, Akudjedu TN, Ahmed M, Holleran L, et al
    Correction to: Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment.
    Neuropsychopharmacology. 2021 Jun 24. pii: 10.1038/s41386-021-01062.

    May 2021
  32. MODINOS G, Richter A, Egerton A, Bonoldi I, et al
    Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes.
    Neuropsychopharmacology. 2021 May 3. pii: 10.1038/s41386-021-01019.
    PubMed     Abstract available

    April 2021
  33. SEITZ-HOLLAND J, Seethaler M, Makris N, Rushmore J, et al
    The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study.
    Neuropsychopharmacology. 2021 Apr 8. pii: 10.1038/s41386-021-00997.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.